ArticleFrontiers in medicine2025
Percutaneous para-levator palpebrae superioris and subconjunctival injection of triamcinolone acetonide for upper eyelid retraction in thyroid-associated ophthalmopathy.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Korean Clinical Practice Framework for Thyroid Eye Disease: Integrating International Recommendations with Survey-Informed Consensus.Endocrinology and metabolism (Seoul, Korea) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid-associated ophthalmopathy (TAO) represents the most prevalent inflammatory condition affecting the orbital region. Upper eyelid retraction, predominantly affecting young female patients, can result in notable cosmetic issues and psychological distress. This study aimed to evaluate the therapeutic effectiveness and safety of percutaneous para-levator palpebrae superioris (PLPS) injections compared to subconjunctival (SC) injections via the upper fornix (SC) for the treatment of upper eyelid retraction secondary to TAO. Methods: This retrospective case-control study encompassed patients with TAO who presented exclusively with upper eyelid retraction. Participants were categorized into either the PLPS group or the SC group based on the injection route. The primary outcome measure was the position of the eyelid margin, quantified by the upper margin reflex distance (MRD1). Secondary outcomes included the incidence of complications and recurrence rates. Results: The study enrolled 45 eyes from 45 patients, with 24 eyes in the PLPS group and 21 eyes in the SC group. Both groups exhibited significant improvement in upper lid retraction following treatment. In the PLPS group, the mean reduction in MRD1 was 1.67 mm from baseline, with a complete response rate of 45.8%, a partial response rate of 37.5%, and an overall response rate of 83.3%. In contrast, the SC group demonstrated a mean MRD1 reduction of 1.71 mm, with complete and partial response rates of 66.7 and 14.3%, respectively, resulting in an overall response rate of 81.0%. There was no statistically significant difference in therapeutic efficacy between the two groups ( Conclusion: The administration of triamcinolone acetonide (TA) via PLPS injection demonstrates comparable efficacy to SC injection for the treatment of upper lid retraction in TAO, with a reduced incidence of elevated intraocular pressure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.